-
公开(公告)号：US11191805B2
公开(公告)日：2021-12-07
申请号：US16854792
申请日：2020-04-21
Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
Inventor： Randolph S. Watnick
Abstract: Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.
-
公开(公告)号：US20200246419A1
公开(公告)日：2020-08-06
申请号：US16854792
申请日：2020-04-21
Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
Inventor： Randolph S. Watnick
Abstract: Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.
-
公开(公告)号：US20160033513A1
公开(公告)日：2016-02-04
申请号：US14773596
申请日：2014-03-13
Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
Inventor： Randolph S. Watnick
IPC: G01N33/574 , A61K38/17 , C12Q1/68
CPC classification number: G01N33/57492 , A61K38/1709 , A61K38/18 , A61K47/6811 , C07K5/12 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N2333/70596 , G01N2800/52
Abstract: Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36.
Abstract translation: 本文提供用于鉴定患有癌症的受试者用Psap肽治疗的方法。 基于CD36的水平鉴定受试者。 本文还提供了基于CD36水平治疗患有癌症的受试者的组合物和方法。
-
公开(公告)号：US20220152146A1
公开(公告)日：2022-05-19
申请号：US17518074
申请日：2021-11-03
Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
Inventor： Randolph S. Watnick
Abstract: Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.
-
公开(公告)号：US10175243B2
公开(公告)日：2019-01-08
申请号：US15684639
申请日：2017-08-23
Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
Inventor： Randolph S. Watnick
IPC: G01N33/574 , C07K5/12 , A61K47/68 , C12Q1/6886 , A61K38/17 , A61K38/18
Abstract: Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36.
-
Patent Agency Ranking
公开(公告)号：US20180088122A1
公开(公告)日：2018-03-29
申请号：US15684639
申请日：2017-08-23
Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
Inventor： Randolph S. Watnick
CPC classification number: G01N33/57492 , A61K38/1709 , A61K38/18 , A61K47/6811 , C07K5/12 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N2333/70596 , G01N2800/52
Abstract: Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36.
-
公开(公告)号：US09921224B2
公开(公告)日：2018-03-20
申请号：US14773596
申请日：2014-03-13
Applicant: Children's Medical Center Corporation
Inventor： Randolph S. Watnick
CPC classification number: G01N33/57492 , A61K38/1709 , A61K38/18 , A61K47/6811 , C07K5/12 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N2333/70596 , G01N2800/52
Abstract: Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36.
-
公开(公告)号：US11840563B2
公开(公告)日：2023-12-12
申请号：US16496142
申请日：2018-03-22
Applicant: Children's Medical Center Corporation
Inventor： Randolph S. Watnick
IPC: C07K14/81 , A61K31/7088 , A61P35/04 , A61K38/00 , A61K39/395 , C07K16/38 , C12N15/113 , A61K39/00
CPC classification number: C07K14/811 , A61K31/7088 , A61K38/005 , A61K39/3955 , A61P35/04 , C07K16/38 , C12N15/1137 , A61K2039/545 , C07K2317/32 , C07K2317/76 , C12N2310/122 , C12N2310/14 , C12N2310/531
Abstract: Provided herein are agents that inhibit the function (e.g., the ability to repress Tsp-1) of Protease, Serine 2 (PRSS2) by inhibiting the binding of PRSS2 to LRP1. Further provided herein are agents that bind to binding domain I of LRP1 and mimic the activity of prosaposin in stimulating Tsp-1 Methods of using these agents in treating cancer are also provided.
-
公开(公告)号：US20230285501A1
公开(公告)日：2023-09-14
申请号：US18103740
申请日：2023-01-31
Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
Inventor： Randolph S. Watnick
IPC: A61K38/08 , C07K7/06 , C07K5/113 , C07K16/00 , A61K38/07 , A61K39/395 , G01N33/50 , C12Q1/6886 , G01N33/74 , G01N33/68 , G01N33/574 , C07K5/11 , A61K45/06 , C07K14/475
CPC classification number: A61K38/08 , C07K7/06 , C07K5/1021 , C07K16/00 , A61K38/07 , A61K39/39591 , G01N33/5023 , C12Q1/6886 , G01N33/74 , G01N33/6893 , G01N33/574 , C07K5/1019 , A61K45/06 , C07K14/475 , C07K2319/30 , C07K2319/31 , A61K2039/505
Abstract: Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
-
公开(公告)号：US10736935B2
公开(公告)日：2020-08-11
申请号：US14367577
申请日：2012-12-21
Applicant: Children's Medical Center Corporation
Inventor： Randolph S. Watnick
IPC: A61K38/08 , C07K7/06 , C07K5/113 , C07K16/00 , A61K38/07 , A61K39/395 , G01N33/50 , C12Q1/6886 , G01N33/74 , G01N33/68 , G01N33/574 , C07K5/11 , A61K45/06 , C07K14/475 , A61K39/00 , A61K38/00
Abstract: Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.018 seconds)
